Schizophrenia drug OK'd for use in adolescents

FDA approves expands uses for Risperdal

Mental health videos

Survey says country seriously stressed out
Oct. 7: More than one-half of Americans recently polled report increased stress over the last year, and one-third categorized their stress levels as extreme. NBC's Dr. Nancy Snyderman reports.

Survey: Economy stressing out Americans

Wechsler: Stress aging is ‘reversible’

Stress levels soaring, survey says

Dealing with financial anxiety

updated 1:17 p.m. ET Aug. 22, 2007

WASHINGTON - The Food and Drug Administration on Wednesday approved a widely used adult psychiatric drug for the treatment of schizophrenia and bipolar disorder in children and adolescents.

The action permits use of Risperdal for schizophrenia in youths aged 13 to 17 and for bipolar disorder for those aged 10 to 17, FDA said.

It was approved last fall for treatment of irritability in autism.

Story continues below ↓

Risperdal, manufactured by Janssen, L.P. of Titusville, N.J., is the No. 3 anti-psychotic drug with $2.3 billion in sales in 2005, according to the pharmaceutical data company IMS Health.

Risperdal was approved for use in adults in 1993.

Until now, FDA said, there has been no approved drug for the treatment of schizophrenia in youths and only lithium is approved for the treatment of bipolar disorder in adolescents.

The dose approved for youths is slightly lower than the adult dose, FDA said.

Drowsiness, fatigue, increase in appetite, anxiety, nausea, dizziness, dry mouth, tremor, and rash were among the most common side effects reported, the agency said.

Click for related content

Pot may hike risk of psychosis, study suggests
Scientists create schizophrenic mice
Sibs of schizophrenics have brain deficits